Reported Earnings • May 14
First quarter 2026 earnings released: US$0.20 loss per share (vs US$0.59 loss in 1Q 2025) First quarter 2026 results: US$0.20 loss per share (improved from US$0.59 loss in 1Q 2025). Revenue: US$806.9k (up 36% from 1Q 2025). Net loss: US$456.4k (loss narrowed 50% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 15
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: US$1.58 loss per share (improved from US$2.57 loss in FY 2024). Revenue: US$2.98m (up 19% from FY 2024). Net loss: US$2.68m (loss narrowed 32% from FY 2024). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 23%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Mar 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (US$5.29m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$7.2m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$2.9m revenue). Reported Earnings • Nov 14
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: US$0.33 loss per share (further deteriorated from US$0.28 loss in 3Q 2024). Revenue: US$1.03m (up 67% from 3Q 2024). Net loss: US$509.9k (loss widened 17% from 3Q 2024). Revenue exceeded analyst estimates by 63%. Earnings per share (EPS) also surpassed analyst estimates by 33%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Duyuru • Nov 03
Xenetic Biosciences, Inc., Annual General Meeting, Dec 11, 2025 Xenetic Biosciences, Inc., Annual General Meeting, Dec 11, 2025. New Risk • Oct 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 48% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (43% average weekly change). Earnings are forecast to decline by an average of 26% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Market cap is less than US$10m (US$9.34m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$7.9m net loss in 3 years). Revenue is less than US$5m (US$2.4m revenue). New Risk • Aug 17
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 26% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 26% per year for the foreseeable future. Market cap is less than US$10m (US$4.41m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$7.9m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$2.4m revenue). Reported Earnings • Aug 14
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: US$0.45 loss per share (improved from US$0.83 loss in 2Q 2024). Revenue: US$589.9k (down 19% from 2Q 2024). Net loss: US$688.7k (loss narrowed 46% from 2Q 2024). Revenue missed analyst estimates by 9.4%. Earnings per share (EPS) exceeded analyst estimates by 30%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. New Risk • Jun 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 29% per year for the foreseeable future. Market cap is less than US$10m (US$4.85m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$11m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$2.6m revenue). Reported Earnings • May 16
First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2025 results: US$0.59 loss per share (improved from US$0.78 loss in 1Q 2024). Revenue: US$593.3k (up 16% from 1Q 2024). Net loss: US$903.1k (loss narrowed 24% from 1Q 2024). Revenue missed analyst estimates by 13%. Earnings per share (EPS) exceeded analyst estimates by 18%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 19
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: US$2.57 loss per share (improved from US$2.71 loss in FY 2023). Revenue: US$2.50m (down 1.6% from FY 2023). Net loss: US$3.96m (loss narrowed 4.2% from FY 2023). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 154%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Duyuru • Nov 22
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting Potential of Co-Administration of DNase I with CAR T Cells in Murine Model of Melanoma Lung Metastasis Xenetic Biosciences, Inc. announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster titled, The synergistic action of DNase I and CAR T cells enhances the therapeutic efficacy of adoptive immunotherapy in the syngeneic murine metastasis model, was presented on behalf of the Company by Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute, at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer, held November 17-20, 2024, in Boston. For the preclinical study co-administration of DNase I with CAR T cells was investigated in a syngeneic B16 murine melanoma model of lung metastasis. Bioluminescent imaging of melanoma metastatic processes has shown that a single injection of DNase I (10 mg/kg) together with CAR T cells suppressed B16-EGFR lung metastasis at early stages in comparison to the vehicle control group and extended survival. Key Highlights: Co-administration of single injection of DNase I (10 mg/kg) with murine EGFR-CAR T cells demonstrated to significantly suppress metastatic tumor burden, decreases the number of metastatic foci, and substantially prolongs survival compared to the CAR T cell monotherapy group. Degrading of NETs by DNase I increases the amount of tumor-infiltrating T and CAR T cells and reduces the immunosuppressive effects of the TME. Tumor immune cell infiltrate analysis revealed that the CD8 population of tumor-infiltrating CAR T cells from the DNase I treated group have lower expression of PD-1 and TIM-3 exhaustion markers. Xenetic continues to advance its DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Preliminary preclinical studies evaluating the combinations of DNase I with chemotherapy and DNase I with immuno-therapies in colorectal cancer models as well as CAR-T therapy have been completed. Reported Earnings • Nov 14
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: US$0.28 loss per share (improved from US$0.69 loss in 3Q 2023). Revenue: US$614.2k (flat on 3Q 2023). Net loss: US$436.7k (loss narrowed 59% from 3Q 2023). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Duyuru • Nov 14
Xenetic Biosciences, Inc. Announces the Presentation of Positive Preclinical Data Xenetic Biosciences, Inc. announced the presentation of positive preclinical data. The poster titled, " DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC," was presented byReid3 Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic at the Society for Immunotherapy of Cancer (SITC) 39 th Annual Meeting held on November 6-10, 2024, in Houston, Texas and virtually. For the preclinical study, mice were implanted with either CT26 or Colon26 cells, both mouse models of MSS/MMRp CRC. The mice were treated with anti-CTLA-4 and either daily or biweekly DNase I (administered either ip or iv). Response was monitored by measuring tumor volume. Key Highlights: Data demonstrates beneficial effects of targeting NETs with systemic DNase I in models of primary tumor and metastatic CRC, improving the efficacy of CTLA-4 immune checkpoint blockade. Both published and newer data suggests that DNase I impedes neutrophil tumor infiltration, promotes CD4 and CD8 T cell infiltration, and enhances intratumoral T cell activation. DNase I plus ??-CTLA-4 combination therapy results in tumor growth inhibition, several CRs and enhanced survival in mice bearing CT26 or Colon26 MSS/MMRp CRC tumors. Dose response evaluations of DNase I combined with ??-CTLA-4, examining both route and frequency of administration was performed. DNase I plus ??-CTLA-4 combination therapy resulted in complete responses (CRs) in mice bearing either CT26 or Colon26 tumors. Significantly, rechallenge of Colon26 and CT26 complete responder animals resulted in no (0 mm3) tumor take or growth, suggesting that DNase I combined with ??-CTLA-4 promoted antitumor immunity and immunological memory. Xenetic's DNase-based oncology platform is designed to target NETs, which are weblike structures composed of extracellular chromatin coated with histones and other proteins. In cancer, NETs are expelled by activated neutrophils into the TME and blood, thereby promoting cancer spread and local and systemic immunosuppression. Reduction of NETs burden via application of Xenetic's proprietary recombinant human DNase I has been shown to improve efficacy of immunotherapy, adoptive cell therapy and chemotherapy in preclinical animal models. Duyuru • Nov 02
Xenetic Biosciences, Inc., Annual General Meeting, Dec 11, 2024 Xenetic Biosciences, Inc., Annual General Meeting, Dec 11, 2024. Reported Earnings • Aug 15
Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat Second quarter 2024 results: US$0.83 loss per share (further deteriorated from US$0.69 loss in 2Q 2023). Revenue: US$726.4k (up 12% from 2Q 2023). Net loss: US$1.27m (loss widened 21% from 2Q 2023). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Duyuru • May 23
Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer Xenetic Biosciences, Inc. announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024. Mr. Parslow is a seasoned executive with over 35 years of experience providing financial and business leadership to the biotech, e-commerce and clean tech industries. Over the course of his career, Mr. Parslow has demonstrated expertise with strategic planning, general management and operations, budgeting, financial planning and analysis, accessing capital markets, M&A, investor relations, risk management, SOX compliance, and SEC/GAAP reporting. Mr. Parslow has served as the Company's Chief Financial Officer since April 2017. Reported Earnings • May 12
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2024 results: US$0.78 loss per share (further deteriorated from US$0.56 loss in 1Q 2023). Revenue: US$510.8k (down 16% from 1Q 2023). Net loss: US$1.20m (loss widened 40% from 1Q 2023). Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 1.3%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. New Risk • May 12
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 32% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 32% per year for the foreseeable future. Market cap is less than US$10m (US$6.00m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$16m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$2.5m revenue). New Risk • Apr 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 33% per year for the foreseeable future. Market cap is less than US$10m (US$6.47m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (US$2.5m revenue). Reported Earnings • Mar 24
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: US$2.71 loss per share (improved from US$4.61 loss in FY 2022). Revenue: US$2.54m (up 49% from FY 2022). Net loss: US$4.13m (loss narrowed 37% from FY 2022). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) exceeded analyst estimates by 3.9%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Duyuru • Mar 19
CLS Therapeutics Discloses its Views on Xenetic Biosciences On March 18, 2024, CLS Therapeutics, Inc. announced that it has sent a letter to the Corporate Secretary of Xenetic Biosciences, Inc., for delivery to the board of directors, CLS and CLS LLC took notice of the stockholders’ vote, on December 6, 2023 at the 2023 annual meeting of the Company’s stockholders, ‘Against’ the compensation of the Company’s named executive officers, advised that they have concerns with the Company’s current management, and advocated for change in the Company’s senior management. Duyuru • Jan 17
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform Xenetic Biosciences, Inc. announced it has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia ("UVA") to advance the development of its systemic DNase program. Xenetic's DNase-based oncology platform is designed to target neutrophil extracellular traps ("NETs"), which are weblike structures composed of extracellular chromatin coated with histones and other proteins. NETs are expelled by activated neutrophils, in response to microbial or pro-inflammatory challenges. However, excessive production or reduced clearance of NETs can lead to aggravated inflammatory and autoimmune pathologies, as well as creation and support of pro-tumorigenic niches in the case of cancer growth and metastasis, thereby potentially limiting response to therapy. Under the terms of the UVA agreements, in addition to advancing Xenetic's existing intellectual property, Xenetic has an option to acquire an exclusive license to any new intellectual property arising from the DNase research program. Allan Tsung, MD, member of the Company's Scientific Advisory Board and Chair of the Department of Surgery at the UVA School of Medicine, will oversee the research conducted under the agreement. As a surgical oncologist and scientist, Dr. Tsung is internationally recognized for leading substantial research on the role of NETs in tumor growth, metastasis, and resistance to existing cancer therapies. Xenetic is working toward its planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy. Duyuru • Nov 14
Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023 Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023, at 10:00 US Eastern Standard Time. Agenda: To elect the Board’s nominees, Grigory Borisenko, James Callaway, Firdaus Jal Dastoor, Jeffrey Eisenberg, Dmitry Genkin, Roger Kornberg, Adam Logal, Moshe Mizrahy and Alexey Vinogradov, to the Board of Directors to serve until the next annual meeting and their successors are duly elected and qualified; to ratify the selection by the Audit Committee of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023; to approve, by non-binding advisory vote, the resolution approving the named executive officer compensation (“Say on Pay”); and to conduct any other business properly brought before the meeting. Reported Earnings • Nov 12
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: US$0.69 loss per share (further deteriorated from US$0.56 loss in 3Q 2022). Revenue: US$611.2k (up 48% from 3Q 2022). Net loss: US$1.06m (loss widened 31% from 3Q 2022). Revenue exceeded analyst estimates by 35%. Earnings per share (EPS) also surpassed analyst estimates by 38%. Revenue is forecast to stay flat during the next 3 years compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 13
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: US$0.69 loss per share (improved from US$1.90 loss in 2Q 2022). Revenue: US$651.0k (up 56% from 2Q 2022). Net loss: US$1.05m (loss narrowed 61% from 2Q 2022). Revenue exceeded analyst estimates by 45%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Reported Earnings • May 12
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: US$0.056 loss per share (improved from US$0.12 loss in 1Q 2022). Revenue: US$605.8k (up 56% from 1Q 2022). Net loss: US$856.6k (loss narrowed 46% from 1Q 2022). Revenue exceeded analyst estimates by 45%. Earnings per share (EPS) also surpassed analyst estimates by 45%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 24
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: US$0.46 loss per share. Revenue: US$1.71m (up 47% from FY 2021). Net loss: US$6.55m (loss widened 16% from FY 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 2.2%. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US. Price Target Changed • Nov 16
Price target increased to US$4.00 Up from US$2.25, the current price target is provided by 1 analyst. New target price is 841% above last closing price of US$0.43. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$0.45 next year compared to a net loss per share of US$0.55 last year. Reported Earnings • Nov 12
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: US$0.056 loss per share (improved from US$0.13 loss in 3Q 2021). Revenue: US$414.3k (up 19% from 3Q 2021). Net loss: US$804.0k (loss narrowed 41% from 3Q 2021). Revenue exceeded analyst estimates by 26%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Major Estimate Revision • Aug 18
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses of -US$0.68 per share expected, vs -US$0.46 per share profit forecast previously. Revenue forecast reaffirmed at US$1.39m. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$4.00 unchanged from last update. Share price fell 6.9% to US$0.82 over the past week. Reported Earnings • Aug 12
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2022 results: US$0.19 loss per share (down from US$0.13 loss in 2Q 2021). Revenue: US$416.7k (up 45% from 2Q 2021). Net loss: US$2.67m (loss widened 142% from 2Q 2021). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 58%. Over the next year, revenue is expected to shrink by 5.9% compared to a 51% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Reported Earnings • May 13
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: US$0.12 loss per share. Revenue: US$389.0k (up 103% from 1Q 2021). Net loss: US$1.59m (loss widened 18% from 1Q 2021). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) missed analyst estimates by 9.1%. Over the next year, revenue is forecast to grow 3.0%, compared to a 25% growth forecast for the industry in the US. Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Member Scientific Advisory Board Greg MacMichael was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 14
Third quarter 2021 earnings released: US$0.13 loss per share (vs US$1.20 loss in 3Q 2020) Third quarter 2021 results: Net loss: US$1.35m (loss narrowed 82% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Major Estimate Revision • Aug 19
Consensus EPS estimates increase to -US$0.55 The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$787.2k to US$799.7k. EPS estimate increased from -US$0.66 to -US$0.55. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$5.00 unchanged from last update. Share price fell 3.4% to US$3.13 over the past week. Reported Earnings • Aug 14
Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2020) Second quarter 2021 results: Net loss: US$1.11m (loss widened 16% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Price Target Changed • Jul 01
Price target increased to US$5.00 Up from US$2.25, the current price target is provided by 1 analyst. New target price is 145% above last closing price of US$2.04. Stock is up 89% over the past year. Duyuru • Dec 16
Xenetic Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million. Xenetic Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,448,980
Price\Range: $2.45
Discount Per Security: $0.1715
Transaction Features: Registered Direct Offering Duyuru • Nov 02
Xenetic Biosciences Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC On October 29, 2020, Xenetic Biosciences, Inc. (the "Company") received a written notification (the "Notice") from the Listing Qualifications Department of the NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the closing bid price for its common stock had been below $1.00 for 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement"). The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market. The company has until April 27, 2021 (the "Compliance Date"), to regain compliance with the Bid Price Requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 for a minimum of ten consecutive business days prior to the Compliance Date. In the event the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify for this second compliance period, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement, or will otherwise be in compliance with other Nasdaq Listing Rules.